South West Strategic Clinical Network Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services
|
|
- Jasper Morris
- 5 years ago
- Views:
Transcription
1 Meeting of the SWAG Network Haematology Site Specific Group (SSG) Wednesday 2 nd November 2016, Engineers House Conference Centre, Clifton Down, Bristol Chair: Dr Deepak Mannari (DM) This meeting was sponsored by Janssen, Celgene and Roche Notes (To be agreed at the next meeting) Actions 1. Welcome and apologies Please see the separate list of attendees and apologies uploaded on to the South West Strategic Clinical Network website here. 2. Service development ,000 genomes project and haematological malignancy Please see the presentation uploaded on to the SWCN website Presented by Dr Andrew Mumford (AM), Clinical Director West of England NHS Genomic Medicine Centre The West of England Genomic Medicine Centre, hosted by UH Bristol with support from Gloucestershire, North Bristol, Weston and RUH Bath, came into fruition 11 months ago, enabling access to the 100,000 genomes project for the West of England patient population. Each host hospital has a local steering group with executive representation. Patients with rare diseases can be consented to give a blood sample, and patients with certain cancer types can be consented to give a blood sample and solid tumour specimen, which are then sent for whole gene sequencing in Cambridge. The service is being rolled out in stages; the first recruit to the rare disease arm was a patient with congenital neutropenia. A breast cancer pathway has been created and the first patient recruited in North Bristol Trust. All pathway processes have to undergo a wet and dry run before approval to commence recruitment of patients can be obtained from the national team. The list of eligible cancers is as detailed in the presentation. Funding generated from the samples sent is used to maintain the GMC workforce, including provision of funding for research teams time in each speciality, and for educational programmes. The project aims to provide the opportunity to install the processes that will transform how future care is delivered. It is hoped to improve diagnostic yield by processing over 4650 samples from patients with rare diseases and their families over the next two years. The use of next generation sequencing, which involves the four steps of fragmentation, ligation, cluster generation and then sequencing, allows for the coding sequence of selected genes (gene panels), and the coding sequence of all Page 1 of 8
2 genes (whole exome), to be processed simultaneously. The patient s sequence is compared with a reference sequence and any differences are highlighted. Two case studies were discussed that showed how results can inform prognosis and treatment. The process for identification of breast cancer patients occurs within the MDT. If a tumour of sufficient size for extraction of DNA is found, the GMC representative will approach the patient, give them information about participation, and liaise with the surgeon, should the patient choose to consent. Participants can choose to consent to have incidental findings fed back to them and the clinical team; tests will be routinely run to check for 20 known actionable gene mutations. At the moment, the whole gene sequencing process takes between 3-6 months to report. It is hoped that this can be reduced to 3-6 weeks, in time to inform clinical decision making. Links to variant level actionability will be included in the GMC report for review by the MDT. Inclusion of haematological malignancies in the GMC project was considered highly relevant due to its prevalence, the risks of recurrence, progression, treatment related morbidity, and due to molecular diagnostics for prognostic estimates and targeting therapies already being standard care, although with variation across the country. Funding for processing 6000 samples (3000 patients) with haematological malignancies has been agreed. This will be rolled out in two stages. Stage 1 is restricted to patients with CLL, AML and Myeloma, who might best be enrolled alongside enrolment into the clinical trials FLAIR, AML 18/19 and MUK9/10, with the necessary samples gathered simultaneously. Stage 2 will include lymphoma; further details can be found within the presentation. CLL recruitment will commence in 2 weeks. AML recruitment will commence from 31 st January It was felt to be preferable for patients to process their diagnosis, consider enrolment into a clinical trial, plus consider enrolment into the GMC, in more than one sitting. After the initial two years, the whole gene sampling will no longer be free, with the expectation that it will be integrated into standard care. Individuals will be sought to lead on the GMC project in each speciality, and then visits will be made to relevant MDTs to discuss how this can be put into practice. Andrew Mumford is to contact Sophie Otton and Sally Moore. AM Information on the different components of the project, educational opportunities and launch events, are available on the website: 3. Review of previous notes and actions/mdt membership As there were no amendments or comments following distribution of the notes from the meeting on the 12 th July 2016, the notes were accepted. Members are to Helen Dunderdale (HD) with details of any new colleagues to add to the distribution list. Page 2 of 8
3 4. Clinical guidelines 4.1 Protocol update and website layout review Please see the separate table of protocols, for update, circulated with the notes. The myeloma protocols were reviewed in a recent breakout meeting and will be finalised by Sarah Murdoch following receipt of responses from attendees. A response was awaited from NHS England on the funding of Panobinostat. The possibility of altering the dosing schedule was discussed. A caveat could be added to the protocol to confirm that this was adapted according to the local clinician s discretion. The protocols developed by other regional teams will be consulted. Following review of the website layout, a request to replace abbreviations with the full regimen product names had been sent to website manager Isobel Rorison. Further suggestions included making the layout more user- friendly by organising alphabetically under headings similar to the Thames Valley website, and separating the lymphoma section into high and low risk. Deepak Mannari will send ideas for the layout to Sarah Murdoch to see if this would be feasible. The PMit CEBO protocol will be moved to the bottom of the list. Mini BEAM and Brentuximab are to be allocated to Lisa Lowry and Nelaribine to Deepak Mannari. Sophie Otton will look at the 2-CDA with Sarah Murdoch. The Velcade containing regimens will be sent to Jeremy Braybrook for authorisation. A link to the national amyloid website protocols will be put on the website. Due to the shorter cancer drug fund review process, the SSG will aim to look at the drugs due for appraisal within each meeting so that the impact can be assessed and relevant protocols developed proactively. SWCN funding for Consultant Pharmacist Sarah Murdoch s work on the protocols will cease at the end of March Further funding for the post needs to be secured so that the protocol work can continue; this will be escalated to the Cancer Operational Group and Cancer Alliance. DM/SM LL DM SO/SM HD 4.2. GP Guidelines GP guidelines have been published on the website with a disclaimer stating that separate Trusts may have individualised pathways and subtle alterations to this guidance. These will be circulated every 2 years for review along with the Clinical Guidelines. A link to the guidelines has been added to the new suspected haematological malignancy referral form. Information on the amount of times the guidelines have been viewed on the website will be brought to a future meeting once the relevant website permissions have been activated. The location of the guidance on the website can be further promoted in GP e-bulletins. Commissioner Beverly Haworth plans to make a quarterly cancer specific newsletter for circulation to GPs and would be happy to include this information. HD BH Page 3 of 8
4 5. Patient experience / living with and beyond cancer 5.1. Request for patient stratification criteria Cancer Network Manager, Jonathan Miller, has asked that site specific groups agree on a consistent approach for the following: The groups into which patients are risk stratified (high risk, low risk etc.) Criteria for determining risk stratification Consultant led face-to-face follow-up agreed for each group (if any) Other scheduled appointments (e.g. nurse led, non-face-to-face) Scheduled diagnostics for upgraded groups (if any) Health & Wellbeing clinics, including timing and whether generic or site specific Signs for concern (including side effects and recurrence) and method of re-access to service. North Bristol Trust has now submitted this information. The CNS in Weston will liaise with their Cancer Manager to provide assistance with the process. It has not been possible for the CNS team to meet and discuss the results of the National Cancer Patient Experience Survey prior to the SSG meeting due to time constraints. A further meeting will be arranged to include discussion on the comments from the survey. 5.2 User representative feedback Angela Absolam, a former patient from Musgrove Park, has agreed to become a user representative member of the group in addition to Victor Barley. A formal user representative feedback form has been created for use across the site specific groups. Feedback from the form will be published in the SSG Annual Reports. 6. Research 6.1 Clinical Trials Update Please see the presentation uploaded on to the SWCN website Presented by Maxine Taylor (MT) Recruitment to haematological trials was going well across the region in comparison with other networks across the country, and recruitment to lymphoma trials was currently second to last in the country. Recruitment data should be entered onto the Edge database as soon as consent has been obtained. It was increasingly important to demonstrate that the NHS can conduct effective research, by recruiting within estimated times and to target, to be eligible to open trials run by the pharmaceutical industry. A traffic light system, as seen in the Page 4 of 8
5 presentation, indicates whether a trial is recruiting as predicted; a black background indicates that the study has yet to recruit. Members of the group are to check the list of trials and inform MT if any information is missing, and if there are any unidentified gaps in the research portfolio that need to be addressed. All RUH Bath is experiencing significant challenges with expanding their research portfolio. AML 18 and 19 are still in set up, with eligible patients currently being sent to the Bristol team, which was not considered a sustainable option in the long term. The Phase 1/11 WT1 gene therapy trial for leukaemia, which is open in Bristol and London, is to be promoted. Research Leads, Sally Moore (SM) and Lisa Lowry plan to increase research activity by coordinating a collaborative network approach. Regular meetings will be convened to enable the following: Expand the network portfolio Review trials open elsewhere to facilitate cross referral Problem solve obstacles to recruitment Share best practice. Trials that are suitable to conduct as a network are to be identified, focusing on trials that are not available elsewhere. The trials that are not meeting recruitment targets are to be reviewed to see if the Principal Investigator would want to close and redirect the resources. Any areas where help is needed will be identified. Current challenges include financial / resource limitations, duplication of work, and competition with non-malignant trials. A network constitution on the essential requirements for conducting research, with practical advice on how this can be achieved, will be compiled and circulated. It was noted that the variety of haematological diseases made it difficult to establish research trials in comparison with other cancer sites. It would be ideal if expressions of interest in commercial studies could be made as a network group, with different studies set up in each Trust. Recruitment could then be sourced from across the region. A commercial study lead will be identified in each centre. It was the opinion of user representative Angela Absolam that patients would be willing to travel for the opportunity to be involved in research. The first research meeting will be held one hour prior to the next SSG meeting. A separate distribution list of relevant staff from the research teams across the region will be compiled. HD Page 5 of 8
6 7. Quality indicators, audits and data collection 7.1 Audit of Hepatitis/HIV Screening Lymphoma fellow Karan Wadehra has commenced work on a network audit on virology testing prior to R-Chemotherapy in patients with newly diagnosed diffuse large B-cell lymphoma, to determine compliance with the SWAG clinical guidelines. These state that all such patients should be screened for Hepatitis B and C. HIV screening has also been included. An audit proforma has been ed to each team across the region, including the Swindon team. The dataset is to include all patients diagnosed from the 1 st January th June Completed profomas are to be submitted to KW by the 30 th November It is hoped that results will show 100% compliance. There is a comments box should any non-compliant result be found, where a reason for omission of the screening test can be included. So far, data has been submitted by UH Bristol and NBT. Results will be presented at the next meeting. The audit will be sent to Weston General Hospital and Yeovil District Hospital. KW 7.2 Audit of Two Week Wait Referral Pro-forma Version 9.3 of the South West Suspected Haematological Malignancy Referral Proforma has been published by Bristol North Somerset and South Gloucestershire CCG. A SWAG SSG nhs.net has been set up for network audits: ubhtr.swagssgaudits@nhs.net If feasible, after processing 2WW referrals in the usual way, any incorrectly completed referral forms or details of the referring GP surgery, NHS number and the reason why the form was not completed appropriately, can be ed to this account. Forms must be sent from another nhs.net account to comply with Information Governance with the subject Haem referral. Feedback on the forms will then be sent to the relevant CCGs approximately every three months, who will then provide feedback to GP practices. Referral forms are processed in a variety of ways across the region. Cancer Managers will be asked if they can recommend who can provide this information. Previous versions of the referral proforma are still being received as the three other CCGs within the region have yet to publish the latest version of the proforma. This should be resolved early in the new year. It would be helpful to have information on the number of two week wait referrals that each Trust receives, the conversion rate to cancer, and whether the referrals was considered appropriate from a clinical point of view. A similar audit had been conducted for the Colorectal SSG, using data pulled from the Somerset Cancer Register. This will be investigated further. HD Page 6 of 8
7 8. Network issues 8.1 Cancer Alliance Update In order to implement the National 5 Year Forward Cancer Strategy, providers and commissioners have been instructed to form Cancer Alliances. For the South West area, it has been decided that there will be 2 Cancer Alliances (CA). The SWAG Cancer Alliance matches with the geography of the SWAG SSGs. For the SWAG CA, it has been agreed that the existing cancer steering groups, Bristol North Somerset, South Gloucestershire, Bath Wiltshire and Swindon, Somerset and Gloucestershire will continue to convene, working to agreed terms of reference. They will nominate 2 to 3 representatives to form the Cancer Alliance steering group, who will represent primary care, secondary care and CCG members. A Clinical and Managerial Lead have been appointed to Chair the Cancer Alliance group: Amelia Randle Macmillan GP from Somerset Deb Lee CEO of Gloucestershire Hospital. Membership will also include patient and charity representatives. Agreement is awaited on whether the SSG Support Service will provide administrative support for the alliance and ensure two way communications between the CA and SSGs. It is hoped that SSGs will be asked to participate in decision making exercises proposed by the alliance. When relevant items are on the CA agenda, SSG Chairs will be invited to contribute to these meetings. The practicalities of how the CA will function, the availability of money and resources, and the agreed standards to deliver are currently being assessed. A report is being drafted detailing the overarching priorities and site specific priorities that have been identified through the SSGs, in the hope that this will be used to inform the Cancer Alliance Work Programme. This has been circulated to the SSG Chairs for their opinions. Administrative support is needed for a chemotherapy group. A workload analysis had shown that it was not feasible for the SSG Support Service to provide this a present. This had been added to the report for the CA to consider. 9. Any other business/date of next meeting User Representative Angela Absolam (AA) is due to attend the Britain Against Cancer all party parliamentary meeting on Tuesday 6th December 2016 and will Page 7 of 8
8 provide relevant feedback to the group at the next meeting. Lisa Lowry will give a presentation on the updated NICE lymphoma guidelines at the next SSG meeting. AA LL Date of next meeting: Wednesday 1 st March 2017, Taunton. -END- Page 8 of 8
Meeting of the SWAG Network Haematology SSG
Meeting of the SWAG Network Haematology SSG Tuesday 21 st November 2017, 14:00-16:30 Penny Brohn Cancer Care, Chapel Pill Lane, Pill, Bristol, BS20 0HH This meeting was sponsored by Celgene and Novartis
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Haematology Cancer Network Site Specific Group.
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Haematology Cancer Network Site Specific Group Annual Report 2014 Version 1.0 1 This annual report was prepared by: Sophie Otton Chair
More informationSouth West Clinical Network Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services
Meeting of the SWAG Network Colorectal SSG 09:30-15:30, Wednesday, 30 th November 2016 Penny Brohn Cancer Care, Chapel Pill Lane, Pill, BS20 OHH THIS MEETING WAS SPONSORED BY NORGINE, MERCK SERONO AND
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
Meeting of the SWAG Network Urology SSG Thursday 15 th March 2018, 13:30-17:00 Spire Specialist Care Centre, 300 Park Avenue, Aztec West Almondsbury, Bristol, BS32 4SY Chairs: Mr Jaspal Phull (JP) & Ms
More informationPlease see the separate list of attendees and apologies uploaded on to the South West Clinical Network website here.
Meeting of the SWAG Network Colorectal Site Specific Group (SSG) 09:30-15:00, Wednesday, 7 th June 2017 Taunton Hyde Park Conference Centre, Hyde Lane, Taunton, Somerset, TA2 8BU Chair: Mr Michael Williamson
More informationSELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)
SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT MDT Lead Clinician ASWCN TAUNTON AND SOMERSET Taunton Lung MDT (11-2C-1) - 2011/12 Dr Sarah Foster Compliance Self Assessment LUNG MDT
More informationSouth West Strategic Clinical Network Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services
Meeting of the SWAG Network Skin Cancer Site Specific Group (SSG) 17 th May 2016, Jurys Inn, Gloucester Road, Cheltenham, GL51 0TS, 09:30-13:00 This meeting was sponsored by DERMAL, PROSTRAKAN and BRISTOL
More informationRichard Watson, Chief Transformation Officer. Dr P Holloway, GP Clinical Lead for Cancer Lisa Parrish, Senior Transformation Lead
GOVERNING BODY Agenda Item No. 08 Reference No. IESCCG 18-02 Date. 23 January 2018 Title Lead Chief Officer Author(s) Purpose Cancer Services Update Richard Watson, Chief Transformation Officer Dr P Holloway,
More informationCancer Improvement Plan Update. September 2014
Cancer Improvement Plan Update September 2014 1 Contents Page 1. Introduction 3 2. Key Achievements 4-5 3. Update on Independent Review Recommendations 6-13 4. Update on IST Recommendations 14-15 5. Update
More informationIntegrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 31 March 2014
Integrated Cancer Services Action Plan Colchester Hospital University NHS Foundation Trust 31 March KEY Implemented, clearly evidenced and externally approved On Track to deliver Some issues narrative
More informationWaiting Times for Suspected and Diagnosed Cancer Patients
Waiting Times for Suspected and Diagnosed Cancer Patients 2015-16 Annual Report Waiting Times for Suspected and Diagnosed Cancer Patients 1 Waiting Times for Suspected and Diagnosed Cancer Patients Prepared
More informationNHS ENGLAND BOARD PAPER
NHS ENGLAND BOARD PAPER Paper: PB.15.12.2016/04 Title: Taking the cancer strategy forward: programme update Lead Director: Professor Sir Bruce Keogh, National Medical Director Cally Palmer, National Cancer
More informationACE Programme SOMERSET INTEGRATED LUNG CANCER PATHWAY. Phases One and Two Final Report
ACE Programme SOMERSET INTEGRATED LUNG CANCER PATHWAY Phases One and Two Final Report July 2017 Introduction This paper presents the learning and actions that have been generated from phase One and Two
More informationHaemato-oncology Clinical Forum. 20 th June 2013
Haemato-oncology Clinical Forum 20 th June 2013 Welcome Dr Majid Kazmi, LCA Haemato-oncology Pathway Group Chair Purpose of today Provide an update on progress of the LCA to date Identify priorities for
More informationNational Cancer Registration Service South West Cancer Alliance Manager NHS England South, South West
Present : Apologies: Meeting of the SWAG Area Cancer Operational Group (formerly ASW) Held on Wednesday 18 th April 2018, 10.00-12.00 Sanford Education Centre, Room 10, 32 Keynsham Road, Cheltenham, GL53
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Soft Tissue Sarcoma Network Site Specific Group. Constitution.
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Soft Tissue Sarcoma Network Site Specific June 2017 Revision due: April 2019 Page 1 of 23 VERSION CONTROL THIS IS A CONTROLLED DOCUMENT.
More information2. Review of previous notes
Meeting of the SWAG Network Colorectal Site Specific Group (SSG) Wednesday, 27 th June 2018, 09:30-15:30 Penny Brohn Cancer Care, Chapel Pill Lane, Pill, Bristol, BS20 0HH THIS MEETING WAS SPONSORED BY
More informationEstablished by NHS England in 2013, we are one of 15 AHSNs across England established to spread innovation at pace and scale.
Friday 22 June 2018 @WEAHSN 1 Overview About the West of England Academic Health Science Network The West of England AHSN is delivering positive healthcare outcomes locally and nationally by driving the
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Cancer of Unknown Primary Network Site Specific Group. Clinical Guidelines
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Cancer of Unknown Primary Network Site Specific Group Revision due: April 2019 Page 1 of 11 VERSION CONTROL THIS IS A CONTROLLED DOCUMENT.
More informationTransforming Cancer Services for London
Programme Director Paul Roche Status Draft Owner Laura Boyd Version 0.4 Author Jennifer Layburn Date 15/05/13 Transforming Cancer Services for London Best Practice Commissioning Pathway for the early detection
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
Meeting of the SWAG Network Gynae SSG Friday 15 th June 2018, 15:30-18:30, Board Room, Trust Headquarters, Bristol Royal Infirmary, Bristol, BS1 3NU THIS MEETING WAS SUPPORTED BY ASTRAZENECA AND STRYKER
More informationSupra Network Sarcoma Advisory Group (SAG) Annual Report
London and South East Sarcoma Network Supra Network Sarcoma Advisory Group (SAG) Annual Report 2011-2012 Hosted by Date: December 2012 Version: 2 Review Date: September 2013 London Cancer Integrated Cancer
More informationFRAILTY PATIENT FOCUS GROUP
FRAILTY PATIENT FOCUS GROUP Community House, Bromley 28 November 2016-10am to 12noon In attendance: 7 Patient and Healthwatch representatives: 4 CCG representatives: Dr Ruchira Paranjape went through the
More informationPersonal and Public Involvement (PPI) Panel Action Plan. September 2010 August 2011
Personal and Public Involvement (PPI) Panel Action Plan September 2010 August 2011 Introduction In 2009, the Southern Health and Social Care Trust developed a draft PPI Action Plan Framework which outlined
More informationSOMERSET PRESCRIBING FORUM
SOMERSET PRESCRIBING FORUM Minutes of the meeting held at Wynford House, Yeovil, on Wednesday 14 November 2012 Present Position Initials Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS Foundation
More informationSouth West Strategic Clinical Network Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services
Meeting of the SWAG Network Colorectal Site Specific Group (SSG) 10:00 16:00, Wednesday, 22nd April 2015, South West House, Blackbrook Park Avenue, Taunton, TA1 2PX Chair: Mr Michael Williamson (MW) This
More informationWork Programme/Service Delivery Plan 2010/2013
Essex and East Suffolk Gynaecological Cancer Network Site Specific Group Work Programme/Service Delivery Plan 2010/2013 Version Number 1.2 Author Members of the NSSG Date Written June 2010 Reviewed May
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
Meeting of the SWAG Network Skin Cancer Site Specific Group (SSG) Wednesday 23 rd May 2018, 09:30-13:30 Penny Brohn Cancer Care, Chapel Pill Lane, Pill, Bristol, BS20 0HH This meeting was sponsored by
More informationLCA Lung Clinical Forum. 21 st October 2014
LCA Lung Clinical Forum 21 st October 2014 Welcome Dr Liz Sawicka Chair - LCA Lung Pathway Group Succession planning Dr Kate Haire Consultant in Public Health Medicine, LCA Commissioning Intentions for
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Head and Neck Cancer Network Site Specific Group. Constitution.
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Head and Neck Cancer Network Site Specific Group Constitution August 2015 Revision due: April 2017 Page 1 of 24 VERSION CONTROL THIS
More informationColorectal Subgroup Minutes Tuesday 22 nd September 2015, 2pm 4pm CTCCU Seminar Room, UHSM
Colorectal Subgroup Minutes Tuesday 22 nd September 2015, 2pm 4pm CTCCU Seminar Room, UHSM ATTENDANCE Sarah Duff Tom Pharaoh Mike Braun Edwin Clark Dave Smith Vanessa Denvir Hannah Leaton Malcolm Wilson
More informationSELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM)
SELF ASSESSMENT REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT MDT Lead Clinician GMCN ROYAL WOLVERHAMPTON HOSPITALS The Royal Wolverhampton Hospitals Trust Lung MDT (11-2C-1) - 2011/12 Dr Angela Morgan
More informationHaematology Regional Group Meeting Monday 18 th October 2010, Antrim Hospital
Haematology Regional Group Meeting Monday 18 th October 2010, Antrim Hospital In attendance: Dr Anne Kyle Clinical Lead Ms Sarah Taggart Ms Caroline McCaughey Ms Margaret Michael Dr Robert Cuthbert Ms
More informationClub administration and record keeping 90 Leadership and governance 315 Publicity and community engagement Club AGM Club Representation
Staffordshire County Federation of Young Farmers Clubs Club Efficiency Competition RULES and GUIDELINES Competition aim: The aim of the Staffordshire County Federation of Young Farmers Clubs (SCFYFC) Club
More informationGRANGE PARK SURGERY LOCAL PATIENT PARTICIPATION REPORT
GRANGE PARK SURGERY LOCAL PATIENT PARTICIPATION REPORT Date: February 2012 1. Introduction The Patient Participation Group (PPG) at Grange Park Surgery was established in 2009 with the first open meeting
More informationNorth Thames Teenager and Young Adults Cancer Network Coordinating Group (TYACNCG) Annual Report
North Thames Teenager and Young Adults Cancer Network Coordinating Group (TYACNCG) Annual Report 2011-12 V0.9 Agreement Chair of the TYA Cancer Network (11-7A-201,202) Position: Divisional Director Name:
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Breast Cancer Network Site Specific Group. Constitution.
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Breast Cancer Network Site Specific Group Constitution June 2015 Revision due: April 2016 Page 1 of 20 VERSION CONTROL THIS IS A CONTROLLED
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance
Meeting of the SWAG Network Urology SSG Thursday 5 th July 2018, 13:30-17:00 Spire Specialist Care Centre, 300 Park Avenue, Aztec West Almondsbury, Bristol, BS32 4SY Chairs: Mr Jaspal Phull (JP) & Ms Lucinda
More informationFrom the Permanent Secretary and HSC Chief Executive
From the Permanent Secretary and HSC Chief Executive Dr Andrew Murrison MP Chair, N. Ireland Affairs Committee Committee Office House of Commons LONDON SW1A 0AA northircom@parliament.uk Castle Buildings
More informationCancer Access Policy. Key Points
Trust Policy Cancer Access Policy Key Points The timescales within which cancer patients are treated is a vital quality measure and key indicator of the quality of cancer services offered at the Trust.
More informationNational Cancer Peer Review Programme
National Cancer Peer Review Programme Julia Hill Acting Deputy National Co-ordinator What is Cancer Peer Review? A quality assurance process for cancer services. An integral part of Improving Outcomes
More informationSWAG Cancer Alliance Programme Manager
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Alliance Minutes of the Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance Board Meeting held on Friday 9 th June 2017 10:00-12:00
More informationDementia Priority Setting Partnership. PROTOCOL March 2012
Dementia Priority Setting Partnership PROTOCOL March 2012 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Dementia Priority Setting Partnership (PSP) and
More informationSouth Norfolk CCG Dementia Strategy and Action Plan Dr Tony Palframan, SNCCG Governing Body Member
Agenda item: 9.4 Subject: Presented by: Submitted to: South Norfolk CCG Dementia Strategy and Action Plan Dr Tony Palframan, SNCCG Governing Body Member Governing Body Date: 28 th July Purpose of paper:
More informationSomerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Brain and CNS Cancer Network Site Specific Group.
Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services Brain and CNS Cancer Network Site Specific Group Annual Report 2015 Version 1.0 1 This Annual Report was prepared by: Venkat Iyer, Chair
More informationActivity Report March 2013 February 2014
West of Scotland Cancer Network Skin Cancer Managed Clinical Network Activity Report March 2013 February 2014 Dr Girish Gupta Consultant Dermatologist MCN Clinical Lead Tom Kane MCN Manager West of Scotland
More informationUpper GI Cancer Network Site-Specific Group. Work Programme/Service Delivery Plan 2011/14
Upper GI Cancer Network Site-Specific Group Work Programme/Service Delivery Plan 2011/14 1 UPPER GI NSSG Work Programme/Service Delivery Plan AGREEMENT COVER SHEET 2011/14 This Work Programme has been
More informationWessex Cancer Alliance. Wessex Cancer Strategic Clinical Network
Wessex Cancer Alliance Wessex Cancer Strategic Clinical Network Chair : Tim Billington Friday 11 th September 2015 Patients are our priority Patients are people Perception versus what is said Pathways
More informationLocal Action Plan SOUTH WEST
1 Local Action Plan -2019 SOUTH WEST Background The south west area covers Cornwall, Devon, Somerset, Wiltshire, Gloucestershire, Bristol and Bath Map As of 31 st December 2016 there were around 270 people
More informationClinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children. January 2013 Reference: NHS England XXX/X/X.
Clinical Commissioning Policy: Chemotherapy Algorithms for Adults and Children January 2013 Reference: NHS England XXX/X/X England 1 NHS England Clinical Commissioning Policy: Chemotherapy Algorithms for
More informationNHS BEXLEY CLINICAL COMMISSIONING GROUP GOVERNING BODY FORMAL MEETING 25 th October 2012
ENCLOSURE : C Agenda Item : 160/12 NHS BEXLEY CLINICAL COMMISSIONING GROUP GOVERNING BODY FORMAL MEETING 25 th October 2012 Adult Hearing AQP Action Required : For APPROVAL Executive Summary The procurement
More informationStreamlining the lung diagnostic pathway (A87)
Streamlining the lung diagnostic pathway (A87) Crawley CCG with Surrey and Sussex Healthcare NHS Trust Evaluation January 2017 Summary A new Straight-to-CT pathway for patients with an abnormal CXR result
More informationHealthwatch Bristol summary of the Bristol Health and Wellbeing Board meeting on 15 February 2017
Healthwatch Bristol summary of the Bristol Health and Wellbeing Board meeting on 15 February 2017 Healthwatch Bristol has a seat on the Health and Wellbeing Board to represent the views of people living
More informationJOB DESCRIPTION. ImROC Business Manager (Mental Health Network) and Senior. Policy Manager (NHS Clinical Commissioners)
JOB DESCRIPTION Job Title: Location: Salary: Reports To: Accountable To: Team Administrator London 21,630 (plus London weighting) ImROC Business Manager (Mental Health Network) ImROC Business Manager (Mental
More informationCancer Outcomes and Services Dataset. What is COSD? Skin Cancers Workshop October 2012
Cancer Outcomes and Services Dataset What is COSD? Skin Cancers Workshop October 2012 17 years ago......cancer registration and careful monitoring of treatment and outcomes are essential... Calman-Hine
More informationLondon Cancer Pathway Board for Haematological Malignancies
Pathway Board for Haematological Malignancies Date: Thursday, 16 th August 16:30-18:00 Venue: Boardroom, 3 rd Floor, UCLP, 170 Tottenham Court Road, London W1T 7HA Chair: Dr Kirit Ardeshna ACTION LOG Action
More informationDCP Newsletter. Welcome. Issue 1 June Key Dates. National Men s Health Week June 2018
DCP Newsletter Issue 1 June 2018 Welcome Hello and a warm welcome to all of our readers of this first edition of the Dorset Cancer Partnership (DCP) newsletter. Each edition of this newsletter will provide
More informationCore Standard 24. Cass Sandmann Emergency Planning Officer. Pat Fields Executive Director for Pandemic Flu Planning
Trust Board Meeting Agenda Item 7 Date: 30 September 2009 Title of Report Recommendations (please outline the purpose of the report and the key issues for consideration/decision) Progress with Pandemic
More informationMS Priority Setting Partnership. PROTOCOL August 2012
MS Priority Setting Partnership PROTOCOL August 2012 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the MS Priority Setting Partnership (PSP) and the basic roles
More informationSarah Ambe Team Manager, Healthwatch Bristol SA Alison Bolam GP Clinical Commissioning Area Lead (Bristol), BNSSG AB
Patient and Public Involvement Forum Minutes of the meeting held on Tuesday 17 th July 2018 at 2pm in the WG Grace Meeting Room, Lower Ground Floor, South Plaza, Marlborough Street, Bristol, BS1 3NX Minutes
More informationShropshire Voluntary and Community Sector Assembly Information Brochure 2017
Voluntary and Community Sector Assembly Information Brochure 2017 A guide for VCSA members, colleagues, commissioners, partners, councillors, town and parish councils and other stakeholders. Welcome to
More informationNewsletter Issue 9 June 2015
Newsletter Issue 9 June 2015 Dementia Improvement Group The Dementia Improvement Group met again at Taunton Racecourse on 4 th June. There was an unprecedented turnout of enthusiastic and committed stakeholders,
More informationCEO Report 2017/ This report reviews and summarises Healthwatch Cambridgeshire and Peterborough activities for 2017/18.
CEO Report 2017/18 Purpose 1. This report reviews and summarises Healthwatch Cambridgeshire and Peterborough activities for 2017/18. Key issues 2. 2017/18 was the first year operating as the new Healthwatch.
More informationProstate Cancer Priority Setting Partnership. PROTOCOL June 2009
Prostate Cancer Priority Setting Partnership PROTOCOL June 2009 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of the Prostate Cancer Priority Setting Partnership
More informationCABINET PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND
CABINET Report No: 105/2017 PUBLIC REPORT 16 May 2017 PROCURING A SUBSTANCE MISUSE & COMMUNITY TREATMENT SERVICE IN RUTLAND Report of the Director of Public Health Strategic Aim: Safeguarding Key Decision:
More informationIntegrated Cancer Services Action Plan. Colchester Hospital University NHS Foundation Trust 30 th June 2014
Integrated Cancer Services Action Plan Colchester Hospital University NHS Foundation Trust 30 th June KEY Implemented, clearly evidenced and externally approved On Track to deliver Some issues narrative
More informationNational Group for Volunteering in NHS Scotland
National Group for Volunteering in NHS Scotland Minutes of the meeting held on Tuesday 15 November 2016 Crammond Room, Scottish Health Services Centre, Edinburgh. Present Neil Galbraith Alan Bigham Rob
More informationGOVERNING BODY REPORT
GOVERNING BODY REPORT DATE OF MEETING: 20th September 2012 TITLE OF REPORT: KEY MESSAGES: NHS West Cheshire Clinical Commissioning Group has identified heart disease as one of its six strategic clinical
More informationWHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE
WHERE NEXT FOR CANCER SERVICES IN WALES? AN EVALUATION OF PRIORITIES TO IMPROVE PATIENT CARE EXECUTIVE SUMMARY Incidence of cancer is rising, with one in two people born after 1960 expected to be diagnosed
More informationCase scenarios: Patient Group Directions
Putting NICE guidance into practice Case scenarios: Patient Group Directions Implementing the NICE guidance on Patient Group Directions (MPG2) Published: March 2014 [updated March 2017] These case scenarios
More informationBREAST IMPLANT SURGERY INDIVIDUAL FUNDING REQUEST POLICY
BREAST IMPLANT SURGERY INDIVIDUAL FUNDING REQUEST POLICY Version: Recommendation by: 1617.V2b Somerset CCG Clinical Commissioning Policy Forum (CCPF) Date Ratified: 13 July 2016 Name of Originator/Author:
More informationR e s e a r c h S t r a t e g y
Sheffield Teaching Hospitals NHS Foundation Trust Academic Directorate of Specialised Cancer R e s e a r c h S t r a t e g y Academic Directorate of Specialised Cancer Research Strategy Executive Summary
More informationMinutes of Healthwatch Sefton Steering Group meeting.
Page1 Minutes of Healthwatch Sefton Steering Group meeting. Held on 11 th December 2013. Board Room. 3 rd Floor, Suite 3B, North Wing, Burlington House Crosby Road North, Waterloo. L22 0LG 1. Welcome,
More informationCommissioning Living with and Beyond Cancer in Yorkshire and Humber; an Overview.
Commissioning Living with and Beyond Cancer in Yorkshire and Humber; an Overview. Document Title An Overview of Commissioning Living with and Beyond Cancer in Yorkshire and Humber Version number: 1 First
More informationDelivering stratified follow-up in primary care for Prostate Cancer Patients - The NCL Approach. Dr Elizabeth Babatunde Macmillan GP
Delivering stratified follow-up in primary care for Prostate Cancer Patients - The NCL Approach Dr Elizabeth Babatunde Macmillan GP Background 2 Objectives Enhance patient experience and outcomes by providing
More informationNational Group for Volunteering in NHS Scotland
National Group for Volunteering in NHS Scotland Minutes of the meeting held on Tuesday 23 August 2016 at Delta House, West Nile Street, Glasgow Present Neil Galbraith Rob Coward Sandie Dickson Marion Findlay
More informationBreast Cancer Pathway Board Minutes of meeting. Wednesday 14 th January 2015, 2pm 5 pm Lecture Theatre, The Nightingale Centre, UHSM
Breast Cancer Pathway Board Minutes of meeting Wednesday 14 th January 2015, 2pm 5 pm Lecture Theatre, The Nightingale Centre, UHSM Attendance Jane Ooi Chandeena Roshanlall Vanessa Pope Mohammed Absar
More informationThis paper outlines the engagement activity that took place, and provides key themes from the 57 written responses received.
Agenda item: 5.4 Subject: Presented by: Prepared by: Submitted to: Specialist Fertility Services Dr Dustyn Saint SNCCG Commissioning Team SNCCG Communications and Engagement Team SNCCG Governing Body Date:
More informationYorkshire and the Humber Strategic Clinical Networks
1. Welcome & Introduction Yorkshire and the Humber Strategic Clinical Networks Yorkshire and the Humber Kidney Care Conservative Care Forum Tuesday 25 th February 2014 1300-1630 Notes Welcome and Introduction
More informationBreast Cancer Pathway Board Minutes of meeting
Breast Cancer Pathway Board Minutes of meeting Monday 9 th March 2015, 2pm 5 pm Boardroom 1, New Alderley House, Victoria Road, East Cheshire NHS Foundation Trust Attendance Mohammed Absar Chandeena Roshanlall
More informationPatient Information Forum
Patient Information Forum Nov 2010 - Update Apologies for cancelling our October meeting (due to unforeseen circumstances). Our next meeting is on 14 December, 9:30am-12:30pm, Seminar Room 2, Cancer Centre,
More informationLiving With and Beyond Cancer where next?
Living With and Beyond Cancer where next? Lesley Smith, Senior Programme Manager, LWBC, NHS England National Network of Colorectal Cancer Nurses, Sept 2018 Disclosure Trustee (unpaid) of the Pelvic Radiation
More informationGuidance document. Patient and Public Involvement in the planning and development of cancer services
Patient and Public Involvement in the planning and development of cancer services Guidance document The Northern Ireland Cancer Network (NICaN) brings individuals and organisations involved in health care
More informationLocal Healthwatch Quality Statements. February 2016
Local Healthwatch Quality Statements February 2016 Local Healthwatch Quality Statements Contents 1 About the Quality Statements... 3 1.1 Strategic context and relationships... 5 1.2 Community voice and
More informationSummary of key points / outcomes/ action Party & date
Haematology Regional Group Meeting Tuesday 25 th May 2010, Antrim Hospital In attendance: Dr Anne Kyle Clinical Lead Ms Sarah Taggart Ms Clare Marshall Dr Tom Lynch Ms Ruth Thompson Ms Caroline McCaughey
More informationINTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM)
INTERNAL VALIDATION REPORT (MULTI-DISCIPLINARY TEAM) Network Trust MDT NECN N Tees & Hartlepool North Tees And Hartlepool Date Self Assessment Completed 23rd July 2009 Date of IV Review 19th June 2009
More informationPublic & Staff Membership Development Strategy 2018/19
Public & Staff Membership Development Strategy 2018/19 Author: Janet Adeyemi Interim in collaboration with the Outreach Working Group Page 1 of 24 Contents Introduction... 3 Background... 4 Strategic objectives...
More informationACTION: FS to send a link to the directory of services
London Cancer Rehabilitation ERG Date: Wednesday, 27 January 2016, 15:00 16:30 Venue: Boardroom, 3 rd Floor, 170 Tottenham Court Road, London, W1T 7HA Chair: Sharon Cavanagh 1. Welcome, Apologies and minutes
More informationNational Cancer Peer Review Sarcoma. Julia Hill Acting Deputy National Co-ordinator
National Cancer Peer Review Sarcoma Julia Hill Acting Deputy National Co-ordinator Improving Outcomes Guidance The Intentions of Improving Outcomes for People with Sarcoma Changes in the provision of care
More informationCancer Transformation Programme
Cancer Transformation Programme Introduction to and supporting documentation for VALUE BASED TRANSFORMATION FUNDING SITE SELECTION November 2016 1 Introduction and Contents The Planning Guidance for 2017-2019
More informationHope Farm Medical Centre Patient Participation Group Meeting Date of Meeting: 17 th January 2017
Meeting: Hope Farm Medical Centre Patient Participation Group Meeting Date of Meeting: 17 th January 2017 Delegates Present & apologies: Present: Ken Salter (chair) Carol Williams Sue MacDonald Keith Anderton
More informationEnsuring effective commissioning of cancer services: A survey of GPs
Ensuring effective commissioning of cancer services: A survey of GPs Effective commissioning of cancer services will be essential if outcomes for cancer patients are to continue improving across the country.
More informationKidney Transplantation
James Lind Alliance Priority Setting Partnership in Kidney Transplantation PROTOCOL Version 1.4 12 th June 2014 Purpose The purpose of this protocol is to set out the aims, objectives and commitments of
More informationActivity Report April 2013 March 2014
North, South East and West of Scotland Cancer Networks Sarcoma National Managed Clinical Network Activity Report April 2013 March 2014 Dr Jeff White Consultant Oncologist NMCN Clinical Lead Lindsay Campbell
More informationHead and Neck Pathway Board Meeting
Head and Neck Pathway Board Meeting Date: Tuesday 10 th September 2013, 14:30-16:30 Venue: The Guild Room, St Bartholomew s Hospital Chair: Mr Simon Whitley ACTION LOG Action Owner Date Agreed Status To
More informationTrust Board of Directors Public. Denise Gale. For Assurance and Information NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE NOT APPLICABLE
NLG(18)014 DATE OF MEETING 30 January 2018 REPORT FOR Trust Board of Directors Public REPORT FROM Richard Sunley, Deputy Chief Executive CONTACT OFFICER Denise Gale SUBJECT Cancer Performance and Backlog
More informationBOTULINUM TOXIN (BOTOX) POLICY HYPERHIDROSIS - PRIOR APPROVAL
BOTULINUM TOXIN (BOTOX) POLICY HYPERHIDROSIS - PRIOR APPROVAL Version: Ratified by: 1617.v2c SCCG COG Date Ratified: 11 May 2016 Name of Originator/Author: Name of Responsible Committee/Individual: IFR
More informationHCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report
HCV Action and Bristol & Severn ODN workshop, 14 th September 2017: Summary report About HCV Action HCV Action is a network, co-ordinated by The Hepatitis C Trust, that brings together health professionals
More informationSafeguarding Business Plan
Safeguarding Business Plan 2015-2018 Contents 1. Introduction 2. The Care Act 3. Organisational Development 4. Vision, Values and Strategic Objectives 5. Financial Plan 6. Appendix A Action Plan 7. Appendix
More informationMCIP Recruitment Pack
MCIP Recruitment Pack Page 1 of 13 Welcome Thank you for the interest you have shown in the MCIP Programme. An exciting partnership has been established to redesign cancer care in Manchester. Funded by
More information